Heart Valve Disease: Latest Advances and Prospects

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 791

Special Issue Editors


E-Mail
Guest Editor
Cardiac Surgery Unit, Clinical and Experimental Department, University of Florence, 50121 Florence, Italy
Interests: cardiovascular surgery; cardiac surgery; aortic diseases; mitral valve annuloplasty; transcatheter aortic valve implantation

E-Mail Website
Guest Editor
Cardiac Surgery F.U., Experimental and Clinical Medicine Department, University of Florence, 50134 Firenze, Italy
Interests: aortic valve disease; electrophysiology/arrhythmia; cardiac; heart failure

Special Issue Information

Dear Colleagues,

Valvular heart disease is a leading cause of cardiovascular morbidity and mortality worldwide, and the resultant disease burden is only projected to increase. In the last few decades, the treatment of valve pathologies has been transformed by advances in medical technology. The development of diagnostic tools and an enhanced clinical understanding of pathophysiology have allowed us to re-examine long-held ideas and think up new possible solutions in this area. A variety of novel, minimally invasive, and transcatheter methods have been developed. In this new Special Issue, we review the latest advances in diagnosis, preoperative planning, and management in the field of heart valve disease and look to future possibilities to discover better treatment solutions.

We look forward to articles and reviews presenting the latest developments in heart valve disease.

Dr. Beatrice Bacchi
Prof. Dr. Massimo Bonacchi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • valve repair
  • valve replacement
  • minimally invasive valve surgery
  • robotic valve surgery
  • ross procedure
  • bicuspid aortic valve
  • prosthetic heart valve
  • tissue-engineered heart valve
  • transcatheter valve procedures
  • heart valve pathophysiology
  • heart valve preoperative planning
  • heart valve instrumental diagnosis
  • artificial intelligence for diagnosis
  • heart valve interventions
  • heart valve diseases

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 294 KiB  
Article
Inflammatory Response Genes’ Polymorphism Associated with Risk of Rheumatic Heart Disease
by Anna Sinitskaya, Maria Khutornaya, Oksana Hryachkova, Maxim Asanov, Alyona Poddubnyak, Anastasia Ponasenko and Maxim Sinitsky
J. Pers. Med. 2024, 14(7), 753; https://doi.org/10.3390/jpm14070753 - 15 Jul 2024
Viewed by 474
Abstract
Rheumatic heart disease (RHD) caused by group A streptococcus infection is one of the most important reasons of cardiovascular morbidity and mortality in low- and middle-income countries. Aberrant host immune response modulated by polymorphisms in inflammatory response genes plays an important role in [...] Read more.
Rheumatic heart disease (RHD) caused by group A streptococcus infection is one of the most important reasons of cardiovascular morbidity and mortality in low- and middle-income countries. Aberrant host immune response modulated by polymorphisms in inflammatory response genes plays an important role in RHD pathogenesis. This study aimed to determine risk-associated polymorphic variants in inflammatory response genes in Caucasian RHD patients. A total of 251 Caucasian RHD patients and 300 healthy donors were recruited for this study, and 27 polymorphic sites in 12 genes (TLR1, TLR2, TLR4, TLR6, IL1B, IL6R, IL6, IL10, IL12RB1, IL12B, TNF and CRP) were analyzed using allele-specific PCR. It was demonstrated that the polymorphic variants rs1800871 and rs1800872 in the IL10 gene, rs 1130864, rs3093077 and rs1205 in the CRP gene, rs375947 in the IL12RB1 gene, rs 5743551 and rs5743611 in the TLR1 gene, and rs3775073 in the TLR6 gene can modify RHD risk in a gender- and age-dependent manner. The obtained results can be used to determine the personalized risk of RHD in healthy donors during medical examination or screening, as well as to develop appropriate early prevention strategies targeting RHD in the risk groups. Full article
(This article belongs to the Special Issue Heart Valve Disease: Latest Advances and Prospects)
Back to TopTop